EMJ GOLD: Pharma news, views and analysis · EMJ
S09 E09: Boehringer's Christoph von der Goltz on setbacks and success in R&D
·22 min·2 clips
Christoph von der Goltz explains why psychiatric drugs fail more often than cardiovascular ones due to the brain's complexity.
As heard by us
A steady look at how pharma teams decide when to persist, pivot, or stop.
This episode treats pharma R&D as a sequence of hard calls: when to keep going, when to pivot, and when to stop. Christoph von der Goltz brings experience from more than 15 years in pharma R&D and board-certified psychiatry, and the conversation is strongest when it gets…
Why you'd press play
When a drug fails, do you pivot, persist, or stop?
Listen to the show on